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1. Introduction
Obesity is one of the greatest public health challenges of the 21st century. Obesity preva‐
lence has been increasing globally at an alarming rate, particularly among children. The pro‐
gressively increased prevalence of obesity over the past decades among children, as well as
adults, is not limited to the US and other industrialized nations but is also evident in devel‐
oping countries [1].The World Health Organization (WHO) estimated the prevalence of obe‐
sity at more than 1 billion overweight adults, with at least 500 million reaching the level of
obese. As this continues to increase, by 2015, WHO estimates the number of overweighed
adults will balloon to 2.3 billion with more than 700 million obese. Worldwide, obesity is
currently responsible for 2–8% of health care costs and approximately 10–13% of deaths [2].
Fundamental causes of the current obesity epidemic are associated with sedentary lifestyles,
increased consumption of energy-dense foods high in saturated fats and sugars and reduced
physical activity. All of which correlate with the profound changes occurring in behavioral
patterns of communities across societies as a consequence of increased urbanization and in‐
dustrialization and often the disappearance of traditional lifestyles [3]. However, it is now
appreciated that the progression to obesity represents a complex interaction of genetics, me‐
tabolism, as well as diet and physical activity level.
Clinically, obesity is defined by measurements of body mass index [4] or waist circumfer‐
ence and waist to hip ratio [5]. Body mass index (BMI) is a simple index weight-to-height
defined as a person's weight in kilograms divided by the square of his/her height in meters
(kg/m2). According to WHO guidelines, a BMI 25 kg/m2 identifies overweight and a BMI of
30 kg/m2 or higher identifies an individual as obese. Physiologically, obesity is an excessive
accumulation of fat in adipose tissue in the form of triglycerides, which can negatively affect
health. Obesity is associated with number of metabolic disorders, increased expression of
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pro-inflammatory markers and elevated risk for various disease including type 2 diabetes,
cardiovascular disease, gastrointestinal disorders, respiratory difficulties, and various types
of cancer [6]. In a more general nature, it has been suggested that obesity may accelerate the
normal process of aging [7] (figure 1).
Figure 1. Obesity accelerates age and age related pathologies. Adapted from [8]
2. Obesity and inflammatory mediators
Adipose tissue has long been regarded as tissue storage of fat in the form of triglycerides;
however, it is now recognized as an endocrine tissue producing a number of different fac‐
tors, including inflammatory-related factors, acting at a physiological level [9].
Two forms of adipose tissues exist in mammals: the brown fat and the white fat (figure 2).
Brown adipose tissue is involved in the regulation of the body temperature. In humans, un‐
til recently, it was thought that brown fat was only present in the newborn and infant [12].
The extensive use of positron emission tomography (PET) in cancer medical imaging has
changed this dogma. An evaluation of fluorodeoxyglucose PET (FDG PET) data from adult
cancer patients indicated a high level of glucose consumption in specific body regions corre‐
sponding to brown fat [10], presumably in order to maintain normal body temperature
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within an air conditioned room as this was not observed when patients were in a warm en‐
vironment. White adipose tissue (WAT) is a source of energy involved in heat insulation
and mechanical cushion. WAT represents around 15-20% of body weight and in obese indi‐
viduals it increases up to 50%. WAT is composed of several different cell types, including
preadipocytes, mature adipocytes, macrophages, endothelial cells which are involved in
WAT homeostasis (Figure 3) [13, 14]. It is worth noting the presence of stem cells in the
WAT, which are extensively studied for their potential in therapeutic reparation and even
for the treatment of obesity and metabolic disorders [15-17].
Figure 2. Brown fat (A) and white fat (B) tissue distribution in adult from [10, 11]
Different functional properties have been identified for WAT depending upon location in
the subcutaneous or visceral areas. For example, a correlation exists between visceral obesity
and increased risk of insulin resistance and cardiovascular diseases, while an increase of
subcutaneous fat is associated with favorable plasma lipid profiles [11]. Adipose tissue was
not usually thought of as an immune or inflammatory organ based upon studies demon‐
strating that loss of adipose tissue is associated with a decrease in markers of inflammation.
It is now well accepted however, that adipose tissue is a key player in the development of
inflammation [19]. Excess fat tissue in the obese environment contributes to a low-grade
chronic inflammation [20] with elevated production of pro-inflammatory cytokines, such as
tumor necrosis factor alpha (TNFα), interleukin -6 (IL-6) and IL-1 [21, 22]. The visceral adi‐
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pocytes significantly contribute in this role as they are metabolically active and produce a
higher level of pro-inflammatory cytokines [11, 23-25].
Figure 3. Cells present in the fat tissue adapted from [13, 18]
Figure 4. Inflammatory factors produced by WAT in obese situations. [26-35]
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WAT is considered as an important organ in the regulation of many pathological processes
by producing several inflammatory factors including, chemokines, cytokines and adipo‐
kines (also named adipocytokines). During the development of obesity expression of these
factors is modified (figure 4).
Adipocytes secrete various chemo-attractants that recruit monocytes into the WAT. Obese
adipose tissue exhibits an increased expression of Monocyte Chemoattractant Protein 1
(MCP-1) and of its receptor CCR2. The signaling of MCP1 / CCR2 has a direct impact on the
development of obesity (for review see [36]). CCL-2, another chemokine with capability to
recruit macrophages, has also a high level of expression in obese adipose tissue; however, it
does not appear to be critical for adipose tissue macrophage recruitment [37]. Several other
chemokines are also likely to play a role in the recruitment of monocytes/macrophages into
the adipose tissue, such as MCP2, MCP4, migration inhibitory factor (MIF), macrophage in‐
flammatory protein-1α (MIP-1α), MIP-1β, or MIP2-α [26, 38]. The adipocytes are not alone
in the elevated inflammatory condition of obesity in that the number of macrophages is also
higher in the obese environment thus, providing an additional cellular source of inflamma‐
tory factors [19].
Experimental animal studies have served a critical role in advancing our knowledge with
regards to the biological relationship between adipose tissue, obesity, and inflammation.
The first study to show a link between obesity and inflammation was the work of Hotamisli‐
gil and colleagues in 1993 in which they demonstrated that TNFα expression was up-regu‐
lated in adipose tissue of genetically obese mice [39]. Additional work reported that the
number of bone-marrow derived macrophages present in white adipose tissue directly cor‐
related with obesity [19]. In addition to macrophages, it has been demonstrated that pre-adi‐
pocytes and mature adipocytes also produce inflammatory factors. The mechanisms that
initiate and trigger the inflammation are not yet totally elucidated, but different hypothesis
have been proposed. A number of factors could trigger an inflammatory response and
among them the saturated fatty acids may play a contributing role. For example, palmitate,
an abundant nutritional fatty acid, could bind to the inflammation-related toll like receptors
(TLR) leading to activation of a signalling cascade and the activation of the transcription fac‐
tor NF-kB (nuclear factor kappa-light-chain-enhancer of activated B cells) [40]. NF-kB is in‐
volved in many cellular processes including immune and inflammatory responses. Upon
activation and nuclear translocation, NF-kB can further induce the production of inflamma‐
tory cytokines, including TNF and IL-1. An alternative, but as relevant a process, is the rec‐
ognition of a diverse range of stress and damage signals by inflammasomes. These are a
group of protein complexes including the Nod-Like Receptor (NLR) proteins that can direct‐
ly activate caspase-1 leading to the secretion of pro-inflammatory cytokines and pyroptotic
cell death (for review see [41]).
Recently inflammasomes and their activation of down-stream events have been shown to
play a major role in the development of obesity, insulin resistance, and diabetes [42, 43].
Another  hypothesis  linking  inflammation  and obesity  is  supported  by  Burcelin’s  group
and involves the intestinal flora equilibrium. In this model, a high fat diet is proposed to
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increase the gram-negative bacteria proportion in the intestine; this increases intestine per‐
meability and the absorption of lipopolysacharide (LPS; the wall component of the gram-
negative  bacteria).  Upon  this  increased  absorption,  TLR  activation  leads  to  an  up-
regulation of the inflammatory response [44, 45]. These two hypotheses are not mutually
exclusive but rather it is likely that the two mechanisms coexist. While the classic localiza‐
tion of  TLRs is  on macrophages our laboratory and others  have shown the presence of
functional Toll-like receptors (TLRs) on human adipocytes including the expression of TLR
type 2 (TLR2) and TLR type 4 (TLR4) [46, 47] providing evidence for the potential of an
adipocyte receptor-mediated response.
Adipokines are defined as soluble mediators that are mainly, but not exclusively, produced
by adipocytes and exert their biological function in an autocrine, paracrine or systemic man‐
ner. Over 50 adipokines have been identified, and they generally function as hormones to
influence energy homeostasis and feeding [22, 48]. The following sections will focus on a re‐
view of two specific adipokines (leptin and adiponectin) and an additional factor (autotaxin)
produced by WAT. Information is presented supporting that these factors and their activa‐
tion may provide an important link between obesity and related inflammatory disorders.
Leptin was identified in 1994 as the 16 kDa protein product of the obese (ob) gene [49]. It
displays immune-regulatory effects by increasing the production of pro-inflammatory cyto‐
kines by macrophages [50]. It is best known as an important regulator of energy balance
through its actions in the brain to suppress appetite and increase energy expenditure [51].
Leptin in the blood enters the brain via a transport mechanism that can be saturated [52].
Upon entry it is believed to act primarily on the hypothalamic centers thus possibly provid‐
ing a target for its effects upon appetite. In addition to the hypothalamus, leptin receptors
(OBR) are widely expressed in numerous extra-hypothalamic regions of the brain, including
the hippocampus, cerebellum, amygdala, and brain stem [53]. There are many splice var‐
iants of the receptor; those with short cytoplasmic domains are expressed in multiple tissues
while the one with long cytoplasmic domains (OB-Rb) are expressed in specific brain re‐
gions. OB-Rb stimulates the JAK/STAT3 pathway and PI3K which are necessary for the lep‐
tin effects on food intake and hepatic glucose metabolism [54, 55].
Adiponectin, a prototypic adipocytokine is an anti-inflammatory adipokine secreted by adi‐
pocytes [56-58]. It plays a major role in regulation of insulin sensitivity and in obesity the lev‐
els of adiponectin are diminished due to a decreased release from WAT [59]. A deficiency in
adiponectin is associated with exaggerated inflammatory response in patients with critical ill‐
ness, including sepsis [32, 60] and with the development of a proinflammatory phenotype in
in animal models of polymicrobial sepsis [61, 62]. Further studies demonstrated that adipo‐
nectin deficiency is associated with increased leukocyte and platelet adhesion as well as blood
brain barrier dysfunction with cecal ligation and puncture induced sepsis in mice [63].
Autotaxin (ATX), also known as ectonucleotide pyrophosphatase phosphodiesterase-2
(ENPP2), is a secreted enzyme with lysophospholipase D (lysoPLD) activity involved in hy‐
drolysis of lysophosphatidylcholine (LPC) into lysophosphatidic acid (LPA) [64]. LPA is bio‐
active phospholipid involved in numerous biological activities, including cell proliferation,
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differentiation, and migration acting via specific G-protein coupled receptors [65]. The LPA
strongly influences proliferation and differentiation of pre-adipocytes via the activation of
LPA1 receptor [66, 67]. Anti-inflammatory properties for LPA have been suggested based
upon the ability to inhibit, in mice, the LPS-induced inflammatory response of macrophages
[68]. The expression of ATX is up-regulated during adipogenesis [69, 70] as well as in adipo‐
cytes from obese-diabetic db/db mice and in adipose tissue obtained from glucose-intolerant
obese women subjects [69, 71]. The role of ATX in inflammation is less clear, but LPA seems
to demonstrate some anti-inflammatory properties as it inhibits LPS-induced inflammation
in cultured macrophages and in mice. Based upon these findings, it has been suggested that
in addition to its role in cancer and LPA production, ATX may be involved in adipose tissue
development and/or obesity-associated pathologies such as diabetes.
3. Influence of obesity on CNS
It is only relatively recently that the concept that obesity could have an effect on the brain
has been emerging. Associations between obesity and various neurological disorders have
been reported including sleep apnea, anxiety, manic depressive disorders, increased risk of
developing cerebrovascular accident (CVA), and other neurological disorders [18, 72]. Addi‐
tional consideration has been raised that obesity may be linked to various progressive and
aging-related neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease
(AD), and autoimmune nervous system diseases like multiple sclerosis.
Over the last decade, a number of magnetic resonance imaging (MRI) and computed tomog‐
raphy (CT) studies have reported alterations in brain morphology of overweight/obese indi‐
viduals. Initial studies demonstrated a higher BMI and/or waist-to-hip ratio in middle-aged
individuals associated with a reduction in whole brain volume [73-75]. A similar association
was observed with temporal lobe atrophy in elderly women [76] with additional evidence of
hippocampal atrophy [77]. Debette et al. [78] reported a link between abdominal fat and re‐
duced brain volume in otherwise healthy middle-aged adults. This study reported an in‐
verse association between various obesity indicators (BMI, waist circumference, waist-to-hip
ratio, and abdominal fat) and brain volume as determined by structural MRI of 733 partici‐
pants. Independent of other obesity indicators, waist-to-hip ratio was found to be associated
with increased temporal horn volume. Pannacciulli et al., 2006 reported gray matter reduc‐
tions in the left postcentral gyrus, bilateral putamen, and right cerebellar regions in obese
individuals as detected using voxel-based morphometry [79]. Gender differences have been
suggested with a male-specific association between increasing BMI and smaller cerebellum,
midbrain, frontal, termporal, and parietal cortex [74]. In a cohort of 95 obese women be‐
tween the ages of 52 and 92, gray matter reductions were reported in the left orbitofrontal,
right inferior frontal, right precentral gyri, and right cerebellar regions [80]. In contrast, in‐
creased volumes in white matter in the frontal, temporal, and parietal lobes were also re‐
ported [80]. In a cross-sectional study of normal elderly individuals showing no sign of
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cognitive deficit, tensor-based morphometry unveiled atrophy in the white and gray matter
of the frontal lobes, anterior cingulate gyrus, hippocampus, and thalamus in both male and
female subjects with a high BMI (BMI > 30) as compared to individuals with a normal BMI
(18.5–25) [81]. Upon further investigation, the brain volume reduction in gray and white
matter was found to be associated with a common variant of the fat mass and obesity associ‐
ated (FTO) gene [82]. Three-dimensional MRI brain maps of 206 healthy elderly participants
showed an association between brain volume and the risk allele of the FTO gene known to
be strongly associated with higher body-mass index. Participants who carried at least one
copy of the allele had marked reductions in the volume of various brain structures com‐
pared to average volumes in non-carriers and in the general population. Carriers of the al‐
lele had, on average, an 8% deficit in the frontal lobe, 12% deficit in the occipital lobe
(percentage units are expressed in terms of the average volumes seen in the general popula‐
tion of carriers and non-carriers). A reduction in temporal lobe volume was observed in par‐
ticipants with a higher BMI, but not in carriers of the risk allele. A pronounced effect of BMI
was seen in carriers of the FTO allele showing volume deficits in all the other lobes of the
brain, as well as in the brain stem and cerebellum. The authors proposed as a strong hypoth‐
esis that “BMI affects brain structure and that FTO exerts some additive detectable effect
over and above whatever the BMI of the person happens to be” [82].
The possible relationship between neurodegeneration and obesity in animal models and in
humans has been studied now for over a decade with a primary focus on the possibility that
obesity and related metabolic disorders exacerbate neurodegeneration and thereby, promote
cognitive decline and increase vulnerability to brain injury [73]. Based upon the identifica‐
tion of hereditary neurodegenerative disorders associated with obesity such as Alstrom,
Bardet-Biedl or Prader-Willi syndromes, some studies have addressed the possibility that
neurodegeneration in the brain may be a causal factor for obesity [83]. A more recent associ‐
ation between obesity and neurological function is based upon correlations with biological
processes of oxidative stress and inflammation. While the causal nature of these processes to
neurodegeneration has not been definitively established, it is widely accepted that neuroin‐
flammation and oxidative stress responses occur with clinical manifestation of the disease.
Given the recent reports of adipokines within the body fat and the elevation of these inflam‐
matory factors with stimulation, a more direct linkage between obesity and various human
diseases, including neurodegenerative disease, has been hypothesized. In the past decade, a
linkage has been demonstrated between being overweight in middle age and increased risk
for AD and other forms of dementia [84, 85]. However, as to date, the exact nature of the
elevated risk has not been identified and characterized. There however, have been a number
of hypotheses put forth, many including a role for inflammation. As previously stated, WAT
can produce an array of inflammatory-related factors, for which expression levels may be
modified in obesity. It has been proposed that an obesity-related chronic low-grade inflam‐
mation can serve to change the environment leading to a priming the brain for subsequent
insults leading to a heightened inflammatory response and possibly exacerbation of the
damage (figure 5).
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Figure 5. low grade chronic inflammation affect the response of the brain to later injury.
Obesity has a major negative impact on cognitive function due to vascular defects, impaired
insulin metabolism and signaling pathway or a defect in glucose transport mechanisms in
brain [86]. As shown in figure 4, leptin level is increased in obesity but there is also evidence
that leptin signaling may become less effective in obesity, provoking a leptin-resistance sta‐
tus [87-89]. Thus, obesity, as it relates to leptin, may be due to a lack of leptin or of its recep‐
tor(s) but may also be a consequence of a signaling defect. Interestingly, leptin has
protective effects in the brain both in vitro and in vivo and thus, has been suggested to be a
good candidate as a link between obesity and neurodegeneration [90]. Similar to leptin, ATX
is increased in obesity. LPA receptors are present in the CNS but the potential effect of ATX
on oxidative stress or neuroinflammation was not known. In a recent study, Awada et al.
[91] demonstrated that ATX synthesis and secretion by the brain immune cell, the microglia,
have a protective effect by mitigating intracellular oxidation. These data suggests a novel
anti-oxidant role for ATX in the brain. In contrast, adiponectin level is lowered with obesity
[92]. In the CNS, adiponectin has been shown to improve cerebrovascular injury in mice [93,
94]. A deficiency in adiponectin in the mouse increases the severity of seizure activity [95]
while presence of adiponectin provides a level of protection to hippocampal neurons against
kainic acid-induced excitotoxicity [96]. It is likely that other factors produced by the WAT
could have some effects on the CNS and further investigations are needed to decipher this
complex network.
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4. Susceptibility of the CNS to obesity in animal studies
Animal models of obesity have been very useful and important for understanding the regu‐
lation of food intake and imbalance in energy expenditure. The initial models examined
spontaneous single gene mutations leading to the loss of the gene function [97]. The first of
these models described is the agouti mouse [98, 99]. In addition to rats, other species have
been used to study obesity related issues. These include, pigs, chicken, and even bats [97,
100, 101]. As several genes have been found to be involved in energy balance regulation, the
advancement of methods for the overexpression or silencing of genes has allowed for a dra‐
matic increase in the number of mouse models of obesity.
There is a growing body of evidence that nutrition could affect the inflammatory status of
the brain [102, 103]. High dietary fat is a significant risk for cerebral oxidative stress devel‐
opment, neuronal inflammation, vascular dementia, AD, and Parkinson disease [104-108].
High fat diet induces a rapid (24 hours) temporary inflammation in the CNS, which can po‐
tentially progress to a chronic condition in obese mice as well as in human and leads to glio‐
sis and mediobasal hypothalamus neuronal injury [109].
In genetic murine model of obesity, an increased susceptibility of CNS to trauma has been
observed; obesity is an aggravating factor in chemical-induced neurodegeneration. In mice
deficient  for  the  leptin  gene  (ob/ob),  the  effects  of  two  neurotoxicants  are  exacerbated,
methamphetamine (METH), which affects dopaminergic neurons and kainic acid (KA), af‐
fecting the  hippocampus [110].  The ob/ob mice  are  also  more  susceptible  to  seizure  in‐
duced  by  the  gamma-aminobutyric  acid  A  receptor  (GABAAR)  antagonist,
pentylenetetrazol (PTZ) [111].
It is now known that in distinct neurogenic sites of the brain the presence of stem/progenitor
cells allows for the generation of new neurons over the full lifespan [112]. This process is
influenced by a number of factors including cytokines, hormones, growth factors, and exer‐
cise [112-116]. The regulatory effects of growth factors demonstrate a level of specificity for
brain regions with brain-derived neurotrophic factor (BDNF) showing prominent effects in
the hippocampus while ciliary neurotrophic factor (CNTF) induces neurogenesis in the hy‐
pothalamus. In this case the neurogenesis occurs in the satiety centers inducing a persistent
weight loss [117]. More importantly, with regards to inflammatory factors, injury to the
brain such as ischemia [118], epilepsy [119], or chemically induced neurodegeneration [120]
induce an increase in neurogenesis. This induction has been termed “injury-induced neuro‐
genesis”. A relationship between adult neurogenesis and obesity has been demonstrated in
the decrease in the turnover of new neurons in the hypothalamic arcuate nucleus (region
playing a key role in body weight regulation) in obese mice (high fat diet or ob/ob) [121].
While the research effort targeted toward this area of the effects of nutrition or obesity on
adult neurogenesis is in its infancy, it is likely that a link similar to what has been found
with neurodegeneration, may be found for molecules such as Omega 3 fatty acids, flavo‐
noids, and polyphenols [122-124].
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5. Conclusion
It is now well accepted that obesity is associated with several pathologies including neuro‐
pathies and the ability of the nervous system to repair following injury. While further re‐
search is needed in characterizing the nature of the effect of obesity on the nervous system
there are current studies suggesting that such effects can be modified. For example, resvera‐
trol or ursolic acid have been shown to attenuate obesity-associated nervous system inflam‐
mation resulting in an improvement of memory deficits in mice fed a high-fat diet. [125,
126]. Given the accelerated increase in obesity and neurodegenerative diseases as well as the
influence of childhood health status and adult disease, there is a critical need to better un‐
derstand the relationship between obesity and the nervous system. Identification of the criti‐
cal factors underlying the various changes seen in the brain and its response to injury as a
function of age, nutritional status, and body mass, i.e., obesity will lay the foundation for
developing therapeutic interventions that will be applicable to the human population.
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